Melanoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 105, 120, 7, 214, 29 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 14, 13, 1, 62 and 14 molecules, respectively.
Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Melanoma - Overview
- Melanoma - Therapeutics Development
- Melanoma - Therapeutics Assessment
- Melanoma - Companies Involved in Therapeutics Development
- Melanoma - Drug Profiles
- Melanoma - Dormant Projects
- Melanoma - Discontinued Products
- Melanoma - Product Development Milestones
For more information about this report visit https://www.researchandmarkets.com/research/h32ffg/melanoma